Revolution Medicines, Inc.
Clinical trials sponsored by Revolution Medicines, Inc., explained in plain language.
Revolution Medicines, Inc.
RVMD
NASDAQ
Develops targeted therapies for RAS-driven cancers.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill targets Hard-to-Treat cancers with a specific gene mutation Results expected Dec 2026 (estimated)
- New pill targets Hard-to-Treat cancers in early trial Results expected Mar 2027 (estimated)
- New drug cocktails aim to shrink Hard-to-Treat gut cancers Results expected May 2027 (estimated)
- New pill targets Hard-to-Treat cancers with RAS mutations Results expected May 2027 (estimated)
- New hope for Hard-to-Treat lung cancer: targeted drug combo trial launches Results expected Jun 2027 (estimated)